Clinical Edge Journal Scan

High D-dimer levels tied to mortality and VTE risks in patients with lung cancer


 

Key clinical point : High circulating D-dimer levels are a risk factor for mortality and venous thromboembolism (VTE) events in patients with lung cancer.

Major finding : The meta-analysis showed that high vs. low circulating D-dimer levels were associated with a higher risk for lung cancer mortality (hazard ratio [HR] 1.62; 95% CI 1.39-1.88). Additionally, the external validation cohort demonstrated that elevated D-dimer levels were associated with a higher risk for overall mortality (HR 1.39; 95% CI 1.13-1.72) and VTE events (HR 3.98; P = .002).

Study details : The data come from a meta-analysis of 19 cohort studies (n = 5819) and an external validation cohort (n = 540).

Disclosures: The study was funded by the Social Development Project of Jiangsu Province, China, and the Project of Hygiene and Health Committee of Jiangsu Province, China. The authors declared no conflicts of interest.

Source: Li J et al. Circulating D-dimers increase the risk of mortality and venous thromboembolism in patients with lung cancer: A systematic analysis combined with external validation. Front Med (Lausanne). 2022;9:853941 (Mar 2). Doi: 10.3389/fmed.2022.853941

Recommended Reading

Preop nivolumab plus chemo ‘a quantum leap’ in NSCLC therapy
MDedge Hematology and Oncology
Advanced ALK+ NSCLC: Elevated cell-free DNA tied to worse outcomes
MDedge Hematology and Oncology
Advanced refractory ROS1+ NSCLC: Lorlatinib is safe and effective in real-world setting
MDedge Hematology and Oncology
EGFR+ stage IV NSCLC: TKI treatment boosts survival
MDedge Hematology and Oncology
Early-stage NSCLC: Adjuvant pembrolizumab improves DFS
MDedge Hematology and Oncology
High prevalence of frailty in patients with lung cancer
MDedge Hematology and Oncology
Stage I NSCLC: No real-world survival benefit with tegafur-uracil chemotherapy
MDedge Hematology and Oncology
Unresectable stage III NSCLC: Platinum-doublet chemotherapy beneficial as second-line therapy
MDedge Hematology and Oncology
Advanced nonsquamous NSCLC: First-line ICI-chemo tops bevacizumab-chemo in OS
MDedge Hematology and Oncology
Advanced NSCLC: Adding antiangiogenic drug to second-line therapy boosts survival outcomes
MDedge Hematology and Oncology